MA54075A - Anticorps monoclonaux antirabiques et cocktail correspondant - Google Patents

Anticorps monoclonaux antirabiques et cocktail correspondant

Info

Publication number
MA54075A
MA54075A MA054075A MA54075A MA54075A MA 54075 A MA54075 A MA 54075A MA 054075 A MA054075 A MA 054075A MA 54075 A MA54075 A MA 54075A MA 54075 A MA54075 A MA 54075A
Authority
MA
Morocco
Prior art keywords
rabs
monoclonal antibodies
cocktail
corresponding cocktail
monoclonal
Prior art date
Application number
MA054075A
Other languages
English (en)
Inventor
Sanjay Bandyopadhyay
Pankaj Kalita
Kevinkumar Kansagra
Sanjeev Kumar Mendiratta
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MA54075A publication Critical patent/MA54075A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054075A 2018-11-02 2019-10-24 Anticorps monoclonaux antirabiques et cocktail correspondant MA54075A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201821041598 2018-11-02

Publications (1)

Publication Number Publication Date
MA54075A true MA54075A (fr) 2022-02-09

Family

ID=68655573

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054075A MA54075A (fr) 2018-11-02 2019-10-24 Anticorps monoclonaux antirabiques et cocktail correspondant

Country Status (9)

Country Link
EP (1) EP3873526B1 (fr)
CN (1) CN113226372A (fr)
BR (1) BR112021008240A2 (fr)
EC (1) ECSP21039816A (fr)
MA (1) MA54075A (fr)
MX (1) MX2021005029A (fr)
PE (1) PE20211056A1 (fr)
PH (1) PH12021550987A1 (fr)
WO (1) WO2020089742A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013048130A2 (fr) * 2011-09-30 2013-04-04 (주)셀트리온 Molécule de liaison pour neutraliser un virus de la rage
DK3220947T3 (da) * 2014-11-18 2020-11-30 Humabs Biomed S A Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf
WO2017027805A1 (fr) * 2015-08-13 2017-02-16 University Of Massachusetts Anticorps humains dirigés contre la rage et utilisations de ces derniers

Also Published As

Publication number Publication date
PE20211056A1 (es) 2021-06-07
MX2021005029A (es) 2021-07-15
ECSP21039816A (es) 2021-09-30
BR112021008240A2 (pt) 2021-10-26
EP3873526B1 (fr) 2024-09-04
PH12021550987A1 (en) 2021-11-08
WO2020089742A1 (fr) 2020-05-07
CN113226372A (zh) 2021-08-06
EP3873526A1 (fr) 2021-09-08

Similar Documents

Publication Publication Date Title
MA53434A (fr) Anticorps anti-tigit
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA52884A (fr) Anticorps anti-il-11
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
MA52212A (fr) Anticorps multivalent
ES2981193T3 (es) Anticuerpos antisirpalpha
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA52152A (fr) Anticorps
MA52366A (fr) Anticorps anti-tl1a optimisés
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
DK3544636T3 (da) Pyrrolobenzodiazepin-antistof-konjugater
SG11202104240TA (en) Cll1-targeting antibody and application thereof
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
MA45543A (fr) Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées
DK3606961T3 (da) Garp-tgf-beta-antistoffer
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA49250A (fr) Nouveaux anticorps anti-cd3
CL2020002333A1 (es) Anticuerpos anti-klk5 y métodos de uso.
MA51134A (fr) Anticorps anti-alpha-synucléine
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées